Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity

Acute kidney injury (AKI) is a collection of clinical syndromes with persistent increases in morbidity and mortality rates. Hyperglycemia is a risk factor for AKI development. Renin-angiotensin-aldosterone system (RAS) disequilibrium and Klotho downregulation also play a pivotal role in the pathogen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimica et biophysica acta. Molecular basis of disease 2022-12, Vol.1868 (12), p.166532-166532, Article 166532
Hauptverfasser: Kale, Ajinath, Shelke, Vishwadeep, Sankrityayan, Himanshu, Dagar, Neha, Gaikwad, Anil Bhanudas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 166532
container_issue 12
container_start_page 166532
container_title Biochimica et biophysica acta. Molecular basis of disease
container_volume 1868
creator Kale, Ajinath
Shelke, Vishwadeep
Sankrityayan, Himanshu
Dagar, Neha
Gaikwad, Anil Bhanudas
description Acute kidney injury (AKI) is a collection of clinical syndromes with persistent increases in morbidity and mortality rates. Hyperglycemia is a risk factor for AKI development. Renin-angiotensin-aldosterone system (RAS) disequilibrium and Klotho downregulation also play a pivotal role in the pathogenesis of AKI. Moreover, the relationship between Klotho and ACE2 (a component of non-conventional RAS) regulation in AKI remains an unexplored area of research. Hence, in this study, we investigated ACE2 and Klotho regulation in AKI using ischemic Wistar rats and NRK52E cells under normal and hyperglycemic conditions. Our findings suggested that hyperglycemia exacerbates renal ischemia-reperfusion injury (IRI)/hypoxia-reperfusion injury (HRI) induced AKI. Systemic and renal Klotho deficiency is a novel hallmark of AKI. Additionally, ACE2 is a protective component of the RAS, and its inhibition/deficiency leads to inflammation, apoptosis, Klotho downregulation, and thus AKI development. However, ACE2 activation resulted in the amelioration of AKI. Importantly, ACE2 plays an important role in Klotho upregulation, which might act as an intermediate for ACE2-mediated reno-protection. In conclusion, ACE2 activator i.e. DIZE restored endogenous ACE2-Ang-(1-7)-Klotho level, inhibited apoptosis and inflammation, and ameliorates IRI/HRI induced AKI under diabetic and non-diabetic conditions. Hence, in future, targeting ACE2-Ang-(1-7)-Klotho axis may prove a novel therapeutic strategy against AKI, where further preclinical and clinical investigations are required to verify the clinical potential of this finding. [Display omitted] •Hyperglycemia is an independent risk factor for IRI/HRI induced AKI.•The systemic as well as renal Klotho deficiency is a novel hallmark of AKI.•ACE2 is a reno-protective component of the RAS where its deficiency leads to AKI.•ACE2 plays an important role in Klotho regulation in AKI.
doi_str_mv 10.1016/j.bbadis.2022.166532
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2708735260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0925443922002034</els_id><sourcerecordid>2708735260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-50cc01da0a73cdccfe594d770955aa296cacb9a497b385733da95b2a699217323</originalsourceid><addsrcrecordid>eNp9kMGKFDEQhoMoOK6-gYccvfSYTjqdiQdhGHZVXPCi4C1UJzW7NfZ0xiQ90G9v1vZsXQqK__uhPsbetmLbirZ_f9oOAwTKWymk3LZ9r5V8xjbtzthG9uLnc7YRVuqm65R9yV7lfBJ1eiM2bPk6xvIYecJcYoJCceJXAr4_3EoOvtD17-0D3_NLLDgVgpGXR0xwwbmQ57lUCh8WDg9AUy4VmgvyXxQmXDhNpzktTSAYsGDmPp5jGihQWV6zF0cYM775t2_Yj7vb74fPzf23T18O-_vGq50ujRbeizaAAKN88P6I2nbBGGG1BpC29-AHC501Q80bpQJYPUjorZWtUVLdsHdr7yXF33N9050pexxHmDDO2Ukjdkbp6qlGuzXqU8w54dFdEp0hLa4V7sm0O7nVtHsy7VbTFfu4YljfuBImlz3h5DFQQl9ciPT_gj_UrYs8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2708735260</pqid></control><display><type>article</type><title>Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kale, Ajinath ; Shelke, Vishwadeep ; Sankrityayan, Himanshu ; Dagar, Neha ; Gaikwad, Anil Bhanudas</creator><creatorcontrib>Kale, Ajinath ; Shelke, Vishwadeep ; Sankrityayan, Himanshu ; Dagar, Neha ; Gaikwad, Anil Bhanudas</creatorcontrib><description>Acute kidney injury (AKI) is a collection of clinical syndromes with persistent increases in morbidity and mortality rates. Hyperglycemia is a risk factor for AKI development. Renin-angiotensin-aldosterone system (RAS) disequilibrium and Klotho downregulation also play a pivotal role in the pathogenesis of AKI. Moreover, the relationship between Klotho and ACE2 (a component of non-conventional RAS) regulation in AKI remains an unexplored area of research. Hence, in this study, we investigated ACE2 and Klotho regulation in AKI using ischemic Wistar rats and NRK52E cells under normal and hyperglycemic conditions. Our findings suggested that hyperglycemia exacerbates renal ischemia-reperfusion injury (IRI)/hypoxia-reperfusion injury (HRI) induced AKI. Systemic and renal Klotho deficiency is a novel hallmark of AKI. Additionally, ACE2 is a protective component of the RAS, and its inhibition/deficiency leads to inflammation, apoptosis, Klotho downregulation, and thus AKI development. However, ACE2 activation resulted in the amelioration of AKI. Importantly, ACE2 plays an important role in Klotho upregulation, which might act as an intermediate for ACE2-mediated reno-protection. In conclusion, ACE2 activator i.e. DIZE restored endogenous ACE2-Ang-(1-7)-Klotho level, inhibited apoptosis and inflammation, and ameliorates IRI/HRI induced AKI under diabetic and non-diabetic conditions. Hence, in future, targeting ACE2-Ang-(1-7)-Klotho axis may prove a novel therapeutic strategy against AKI, where further preclinical and clinical investigations are required to verify the clinical potential of this finding. [Display omitted] •Hyperglycemia is an independent risk factor for IRI/HRI induced AKI.•The systemic as well as renal Klotho deficiency is a novel hallmark of AKI.•ACE2 is a reno-protective component of the RAS where its deficiency leads to AKI.•ACE2 plays an important role in Klotho regulation in AKI.</description><identifier>ISSN: 0925-4439</identifier><identifier>EISSN: 1879-260X</identifier><identifier>DOI: 10.1016/j.bbadis.2022.166532</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>ACE2 ; Acute kidney injury ; Diminazene aceturate ; Hyperglycemia ; Klotho ; MLN-4760</subject><ispartof>Biochimica et biophysica acta. Molecular basis of disease, 2022-12, Vol.1868 (12), p.166532-166532, Article 166532</ispartof><rights>2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-50cc01da0a73cdccfe594d770955aa296cacb9a497b385733da95b2a699217323</citedby><cites>FETCH-LOGICAL-c385t-50cc01da0a73cdccfe594d770955aa296cacb9a497b385733da95b2a699217323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbadis.2022.166532$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids></links><search><creatorcontrib>Kale, Ajinath</creatorcontrib><creatorcontrib>Shelke, Vishwadeep</creatorcontrib><creatorcontrib>Sankrityayan, Himanshu</creatorcontrib><creatorcontrib>Dagar, Neha</creatorcontrib><creatorcontrib>Gaikwad, Anil Bhanudas</creatorcontrib><title>Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity</title><title>Biochimica et biophysica acta. Molecular basis of disease</title><description>Acute kidney injury (AKI) is a collection of clinical syndromes with persistent increases in morbidity and mortality rates. Hyperglycemia is a risk factor for AKI development. Renin-angiotensin-aldosterone system (RAS) disequilibrium and Klotho downregulation also play a pivotal role in the pathogenesis of AKI. Moreover, the relationship between Klotho and ACE2 (a component of non-conventional RAS) regulation in AKI remains an unexplored area of research. Hence, in this study, we investigated ACE2 and Klotho regulation in AKI using ischemic Wistar rats and NRK52E cells under normal and hyperglycemic conditions. Our findings suggested that hyperglycemia exacerbates renal ischemia-reperfusion injury (IRI)/hypoxia-reperfusion injury (HRI) induced AKI. Systemic and renal Klotho deficiency is a novel hallmark of AKI. Additionally, ACE2 is a protective component of the RAS, and its inhibition/deficiency leads to inflammation, apoptosis, Klotho downregulation, and thus AKI development. However, ACE2 activation resulted in the amelioration of AKI. Importantly, ACE2 plays an important role in Klotho upregulation, which might act as an intermediate for ACE2-mediated reno-protection. In conclusion, ACE2 activator i.e. DIZE restored endogenous ACE2-Ang-(1-7)-Klotho level, inhibited apoptosis and inflammation, and ameliorates IRI/HRI induced AKI under diabetic and non-diabetic conditions. Hence, in future, targeting ACE2-Ang-(1-7)-Klotho axis may prove a novel therapeutic strategy against AKI, where further preclinical and clinical investigations are required to verify the clinical potential of this finding. [Display omitted] •Hyperglycemia is an independent risk factor for IRI/HRI induced AKI.•The systemic as well as renal Klotho deficiency is a novel hallmark of AKI.•ACE2 is a reno-protective component of the RAS where its deficiency leads to AKI.•ACE2 plays an important role in Klotho regulation in AKI.</description><subject>ACE2</subject><subject>Acute kidney injury</subject><subject>Diminazene aceturate</subject><subject>Hyperglycemia</subject><subject>Klotho</subject><subject>MLN-4760</subject><issn>0925-4439</issn><issn>1879-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMGKFDEQhoMoOK6-gYccvfSYTjqdiQdhGHZVXPCi4C1UJzW7NfZ0xiQ90G9v1vZsXQqK__uhPsbetmLbirZ_f9oOAwTKWymk3LZ9r5V8xjbtzthG9uLnc7YRVuqm65R9yV7lfBJ1eiM2bPk6xvIYecJcYoJCceJXAr4_3EoOvtD17-0D3_NLLDgVgpGXR0xwwbmQ57lUCh8WDg9AUy4VmgvyXxQmXDhNpzktTSAYsGDmPp5jGihQWV6zF0cYM775t2_Yj7vb74fPzf23T18O-_vGq50ujRbeizaAAKN88P6I2nbBGGG1BpC29-AHC501Q80bpQJYPUjorZWtUVLdsHdr7yXF33N9050pexxHmDDO2Ukjdkbp6qlGuzXqU8w54dFdEp0hLa4V7sm0O7nVtHsy7VbTFfu4YljfuBImlz3h5DFQQl9ciPT_gj_UrYs8</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Kale, Ajinath</creator><creator>Shelke, Vishwadeep</creator><creator>Sankrityayan, Himanshu</creator><creator>Dagar, Neha</creator><creator>Gaikwad, Anil Bhanudas</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20221201</creationdate><title>Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity</title><author>Kale, Ajinath ; Shelke, Vishwadeep ; Sankrityayan, Himanshu ; Dagar, Neha ; Gaikwad, Anil Bhanudas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-50cc01da0a73cdccfe594d770955aa296cacb9a497b385733da95b2a699217323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ACE2</topic><topic>Acute kidney injury</topic><topic>Diminazene aceturate</topic><topic>Hyperglycemia</topic><topic>Klotho</topic><topic>MLN-4760</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kale, Ajinath</creatorcontrib><creatorcontrib>Shelke, Vishwadeep</creatorcontrib><creatorcontrib>Sankrityayan, Himanshu</creatorcontrib><creatorcontrib>Dagar, Neha</creatorcontrib><creatorcontrib>Gaikwad, Anil Bhanudas</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimica et biophysica acta. Molecular basis of disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kale, Ajinath</au><au>Shelke, Vishwadeep</au><au>Sankrityayan, Himanshu</au><au>Dagar, Neha</au><au>Gaikwad, Anil Bhanudas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity</atitle><jtitle>Biochimica et biophysica acta. Molecular basis of disease</jtitle><date>2022-12-01</date><risdate>2022</risdate><volume>1868</volume><issue>12</issue><spage>166532</spage><epage>166532</epage><pages>166532-166532</pages><artnum>166532</artnum><issn>0925-4439</issn><eissn>1879-260X</eissn><abstract>Acute kidney injury (AKI) is a collection of clinical syndromes with persistent increases in morbidity and mortality rates. Hyperglycemia is a risk factor for AKI development. Renin-angiotensin-aldosterone system (RAS) disequilibrium and Klotho downregulation also play a pivotal role in the pathogenesis of AKI. Moreover, the relationship between Klotho and ACE2 (a component of non-conventional RAS) regulation in AKI remains an unexplored area of research. Hence, in this study, we investigated ACE2 and Klotho regulation in AKI using ischemic Wistar rats and NRK52E cells under normal and hyperglycemic conditions. Our findings suggested that hyperglycemia exacerbates renal ischemia-reperfusion injury (IRI)/hypoxia-reperfusion injury (HRI) induced AKI. Systemic and renal Klotho deficiency is a novel hallmark of AKI. Additionally, ACE2 is a protective component of the RAS, and its inhibition/deficiency leads to inflammation, apoptosis, Klotho downregulation, and thus AKI development. However, ACE2 activation resulted in the amelioration of AKI. Importantly, ACE2 plays an important role in Klotho upregulation, which might act as an intermediate for ACE2-mediated reno-protection. In conclusion, ACE2 activator i.e. DIZE restored endogenous ACE2-Ang-(1-7)-Klotho level, inhibited apoptosis and inflammation, and ameliorates IRI/HRI induced AKI under diabetic and non-diabetic conditions. Hence, in future, targeting ACE2-Ang-(1-7)-Klotho axis may prove a novel therapeutic strategy against AKI, where further preclinical and clinical investigations are required to verify the clinical potential of this finding. [Display omitted] •Hyperglycemia is an independent risk factor for IRI/HRI induced AKI.•The systemic as well as renal Klotho deficiency is a novel hallmark of AKI.•ACE2 is a reno-protective component of the RAS where its deficiency leads to AKI.•ACE2 plays an important role in Klotho regulation in AKI.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.bbadis.2022.166532</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0925-4439
ispartof Biochimica et biophysica acta. Molecular basis of disease, 2022-12, Vol.1868 (12), p.166532-166532, Article 166532
issn 0925-4439
1879-260X
language eng
recordid cdi_proquest_miscellaneous_2708735260
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects ACE2
Acute kidney injury
Diminazene aceturate
Hyperglycemia
Klotho
MLN-4760
title Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Klotho%20restoration%20via%20ACE2%20activation:%20A%20potential%20therapeutic%20strategy%20against%20acute%20kidney%20injury-diabetes%20comorbidity&rft.jtitle=Biochimica%20et%20biophysica%20acta.%20Molecular%20basis%20of%20disease&rft.au=Kale,%20Ajinath&rft.date=2022-12-01&rft.volume=1868&rft.issue=12&rft.spage=166532&rft.epage=166532&rft.pages=166532-166532&rft.artnum=166532&rft.issn=0925-4439&rft.eissn=1879-260X&rft_id=info:doi/10.1016/j.bbadis.2022.166532&rft_dat=%3Cproquest_cross%3E2708735260%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2708735260&rft_id=info:pmid/&rft_els_id=S0925443922002034&rfr_iscdi=true